Shares of Endocyte, Inc. (NASDAQ:ECYT) were down 0.6% during trading on Thursday . The company traded as low as $4.70 and last traded at $4.86. Approximately 830,280 shares were traded during trading, a decline of 70% from the average daily volume of 2,810,750 shares. The stock had previously closed at $4.83.
Several equities analysts have weighed in on the company. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Cowen and Company reissued a “hold” rating on shares of Endocyte in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Endocyte has a consensus rating of “Hold” and an average price target of $7.00.
The stock’s market capitalization is $204.36 million. The firm’s 50-day moving average is $2.27 and its 200 day moving average is $2.00.
Endocyte (NASDAQ:ECYT) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The company had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the previous year, the company posted ($0.25) EPS. On average, equities research analysts predict that Endocyte, Inc. will post ($1.06) EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Stifel Financial Corp raised its stake in Endocyte by 3.9% during the 1st quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,711 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Endocyte by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 6,469 shares during the last quarter. Teachers Advisors LLC raised its stake in Endocyte by 17.1% during the 4th quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 9,506 shares during the last quarter. RMB Capital Management LLC raised its stake in Endocyte by 8.8% during the 1st quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock valued at $681,000 after buying an additional 21,500 shares during the last quarter. Finally, FMR LLC raised its stake in Endocyte by 0.7% during the 1st quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock valued at $9,018,000 after buying an additional 24,625 shares during the last quarter. Institutional investors and hedge funds own 28.79% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Endocyte, Inc. (ECYT) Trading Down 0.6%” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2955856/endocyte-inc-ecyt-trading-down-0-6.html.
Endocyte Company Profile
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.